IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal Develop at Discordant Rates by Schager, Anna et al.
 
 
IgG Responses to Porins and Lipopolysaccharide
within an Outer Membrane-Based Vaccine against
Nontyphoidal  Develop at Discordant Rates
Schager, Anna; Dominguez Medina, Carmen; Necchi, Francesca ; Micoli, Francesca; Goh,
Yun Shan; Goodall, Margaret; Flores-Langarica, Adriana; Bobat, Saeeda; Jones, Charlotte;
Arcuri, Melissa; Marini, Arianna; King, Lloyd David William; Morris, Faye; Anderson, Graham;
Toellner, Kai-Michael; Henderson, Ian; López-Macías, Constantino; MacLennan, Calman A. ;
Cunningham, Adam
DOI:
10.1128/mBio.02379-17
http://mbio.asm.org/content/9/2/e02379-17
10.1128/mBio.02379-17
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Schager, A, Dominguez-Medina, CC, Necchi, F, Micoli, F, Goh, YS, Goodall, M, Flores-Langarica, A, Bobat, S,
Cook, C, Arcuri, M, Marini, A, King, LDW, Morris, F, Anderson, G, Toellner, K-M, Henderson, I, López-Macías,
C, MacLennan, CA & Cunningham, A 2018, 'IgG Responses to Porins and Lipopolysaccharide within an Outer
Membrane-Based Vaccine against Nontyphoidal  Develop at Discordant Rates', mBio, vol. 9, no. 2, e02379-17.
https://doi.org/10.1128/mBio.02379-17, https://doi.org/http://mbio.asm.org/content/9/2/e02379-17,
https://doi.org/10.1128/mBio.02379-17
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Published in mBio on 06/03/2018
DOI: 10.1128/mBio.02379-17
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
IgG Responses to Porins and Lipopolysaccharide within an
Outer Membrane-Based Vaccine against Nontyphoidal
Salmonella Develop at Discordant Rates
Anna E. Schager,a,b C. Coral Dominguez-Medina,a Francesca Necchi,b Francesca Micoli,b Yun Shan Goh,b* Margaret Goodall,a
Adriana Flores-Langarica,a Saeeda Bobat,a* Charlotte N. L. Cook,a Melissa Arcuri,a,b Arianna Marini,a,b* Lloyd D. W. King,a
Faye C. Morris,a* Graham Anderson,a Kai-Michael Toellner,a Ian R. Henderson,a Constantino López-Macías,c
Calman A. MacLennan,b* Adam F. Cunninghama
aInstitute for Microbiology and Infection, School of Immunology and Immunotherapy, Institute for Biomedical
Research, University of Birmingham, Birmingham, United Kingdom
bGSK Vaccines Institute for Global Health, Siena, Italy
cMedical Research Unit on Immunochemistry, National Medical Center “SigloXXI,” Specialties Hospital, Mexican
Institute for Social Security (IMSS), Mexico City, Mexico
ABSTRACT Antibodies acquired after vaccination or natural infection with Gram-
negative bacteria, such as invasive Salmonella enterica serovar Typhimurium, can
protect against disease. Immunization with naturally shed outer membrane vesicles
from Gram-negative bacteria is being studied for its potential to protect against
many infections, since antigens within vesicles maintain their natural conformation
and orientation. Shedding can be enhanced through genetic modiﬁcation, and the
resulting particles, generalized modules for membrane antigens (GMMA), not only
offer potential as vaccines but also can facilitate the study of B-cell responses to
bacterial antigens. Here we show that the response to immunization with GMMA
from S. Typhimurium (STmGMMA) provides B-cell-dependent protection and induces
antibodies to two immunodominant antigens, lipopolysaccharide (LPS) and porins.
Antibodies to LPS O antigen (O-Ag) markedly enhance protection in the spleen, but
this effect is less marked in the liver. Strikingly, IgG responses to LPS and porins
develop with distinct kinetics. In the ﬁrst week after immunization, there is a
dramatic T-cell-independent B1b-cell-associated induction of all IgG isotypes, ex-
cept IgG1, to porins but not to LPS. In contrast, production of IgG1 to either an-
tigen was delayed and T cell dependent. Nevertheless, after 1 month, cells in the
bone marrow secreting IgG against porins or LPS were present at a similar fre-
quency. Unexpectedly, immunization with O-Ag-deﬁcient STmGMMA did not sub-
stantially enhance the anti-porin response. Therefore, IgG switching to all anti-
gens does not develop synchronously within the same complex and so the rate
of IgG switching to a single component does not necessarily reﬂect its frequency
within the antigenic complex.
IMPORTANCE Vaccines save millions of lives, yet for some infections there are
none. This includes some types of Salmonella infections, killing hundreds of thou-
sands of people annually. We show how a new type of vaccine, called GMMA, that is
made from blebs shed from the Salmonella cell wall, works to protect against infec-
tion in mice by inducing host proteins (antibodies) speciﬁcally recognizing bacterial
components (antigens). The rate of development of IgG antibody to antigens within
GMMA occurred with different kinetics. However, the antibody response to GMMA
persists and is likely to provide prolonged protection for those who need it. These
results help show how antibody responses to bacterial antigens develop and how
vaccines like GMMA can work and help prevent infection.
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Bacterial infections remain a serious threat to human and veterinary health. Novel,cost-effective vaccination strategies are needed for use in resource-limited regions
of the world, such as sub-Saharan Africa. A promising approach to generate vaccines
against Gram-negative bacteria is to use native outer membrane vesicles (NOMVs),
which are blebs of outer membrane naturally shed by bacteria. Key advantages of
NOMVs include their potential safety for use in humans (1), enrichment for surface
antigens that are often recognized by B cells, and maintenance of these antigens in
their natural conformation and orientation (2). Furthermore, these nano-sized, nonvi-
able antigens can be used in immunocompromised individuals and overcome the
potential risks of infection associated with the use of live, attenuated vaccines in such
populations.
To enhance the production of OMVs from Gram-negative bacteria without using
detergents, mutations can be introduced that result in hyperblebbing. This avoids the
potential for detergents to alter the conformation of some antigens within the particles
and to extract some lipoproteins from them. Thus, high yields can be obtained from
bacteria in which the Tol-Pal pathway is disrupted by deletion of tolR (3). The resulting
particles are similar to NOMVs and known as generalized modules of membrane
antigens (GMMA). GMMA and NOMVs have been assessed as vaccine platforms to
induce protective immunity against several Gram-negative bacterial pathogens such
as Escherichia coli, Shigella, Salmonella, and Neisseria (1, 3–19). Invasive nontyphoidal
Salmonella (iNTS) infections are a serious health concern and are estimated to kill over
650,000 people annually worldwide (20). Two Salmonella enterica serovars, Typhimu-
rium and Enteritidis, are predominantly associated with iNTS disease in children under
5 years old in sub-Saharan Africa, and iNTS infections are a serious problem in
individuals of any age with HIV infection. Despite this, there is no vaccine against iNTS
infections that is licensed for use in humans (21–23). NOMVs have previously been
shown to have potential against experimental iNTS infections (8), and one likely
mechanism for their mode of action is the induction of a protective antibody (Ab) that
can play a role in the control of such infections (24). Antibodies to several S. Typhimu-
rium antigens have been shown to be protective, including the O antigen (O-Ag) of the
lipopolysaccharide (LPS) molecule (25–30) and porins (31–35), including OmpD (33).
While antibodies to LPS and porins are detectable after natural infection, little is known
about the relative kinetics of their induction, particularly in the context of OMVs and
GMMA. Furthermore, the relative persistence of responses to these antigens has
received limited attention. This is important to know, as both the induction and the
maintenance of responses to antigen are key requisites of any vaccine that provides
long-lasting immunity.
In this study, mice were immunized with GMMA from S. Typhimurium (STmGMMA)
and the relative kinetics of the induction of antibodies of different IgG isotypes to
porins and LPS were addressed. The results show that IgG responses to LPS develop
more slowly than IgG responses to porins, with a paucity of IgG1 to both antigens
detected, compared to other IgG isotypes, until the second week after immunization.
Unexpectedly, the induction of IgG of all isotypes except IgG1 was independent of T
cells, possibly reﬂecting the B1b-cell response to STmGMMA observed. Collectively,
these data show that B-cell responses to all antigens do not develop in parallel within
the same GMMA antigenic complex and that the extent of the early IgG response does
not necessarily reﬂect the relative abundance of an antigen within a complex.
RESULTS
Immunization with STmGMMA induces protection that is dependent upon B
cells STmGMMA were puriﬁed from the supernatants of cultures of S. Typhimurium
SL1418 ΔtolR. Transmission electron microscopy (TEM) showed that STmGMMA are
spherical particles of various sizes, with diameters in the range of approximately 20 to
Schager et al. ®
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250 nm, similar to previous reports describing GMMA (3, 5, 6) and OMVs (2, 8) (Fig. 1A).
After immunization of C57BL/6 mice intraperitoneally (i.p.) with 1 g of STmGMMA,
there was a rapid induction of IgM and IgG, with both detectable by day 4, and while
IgM titers remained relatively stable, IgG titers continued rising over the following
weeks (Fig. 1B). Mice immunized with STmGMMA for 14 days showed a 100-fold
reduction in bacterial burdens in the spleen and liver when challenged i.p. with
attenuated S. Typhimurium SL3261. In contrast, B-cell-deﬁcient mice immunized in the
same way did not have any signiﬁcant bacterial burden reduction at these sites
(Fig. 1C). Experiments where nonimmunized mice were infected for 24 h with bacteria
that had been opsonized with serum from nonimmunized or STmGMMA-immunized
mice showed that the presence of anti-STmGMMA Ab was sufﬁcient to reduce bacterial
colonization of the spleen and liver (Fig. 1D). Therefore, immunization with STmGMMA
induces rapid IgM and IgG responses and confers protection that is dependent upon B
cells.
IgG switching and GC are induced rapidly after immunization with STmGMMA.
Since B cells were important for the protection afforded by STmGMMA immunization,
FIG 1 STmGMMA induce antibodies that can protect against infection. (A) Electron microscopy of STmGMMA. STmGMMA
were puriﬁed from S. Typhimurium ΔtolR culture supernatant, prepared for staining, and visualized by TEM. (B) Mice were
immunized i.p. with 1 g of STmGMMA for the times indicated, and serum samples were subjected to ELISA for
anti-STmGMMA IgM (left) and IgG (right). Each dot represents one serum sample. (C) WT (left) or B-cell-deﬁcient (IgH/)
(right) mice immunized once i.p. with 1 g of STmGMMA for 14 days were infected i.p. with 5 105 CFU of S. Typhimurium
SL3261, and bacteria in the spleen (left) and liver (right) were enumerated 5 days postinfection. Each dot represents one
mouse, and graphs are representative of two independent experiments. (D) Naive WT mice were infected i.p. with 5 
105 CFU of S. Typhimurium SL3261 that were preopsonized with serum from nonimmunized mice or serum from mice
immunized with STmGMMA for 35 days. Bacteria in the spleen (left) and liver (right) were enumerated at 24 h postinfection.
Each dot represents one mouse, and results representative of two independent experiments are shown. The Mann-Whitney
U test was used to determine signiﬁcant differences between groups linked by bars. NI, nonimmunized; NS, nonsigniﬁcant;
*, P  0.05.
Responses to Outer Membrane Particles from Salmonella ®
March/April 2018 Volume 9 Issue 2 e02379-17 mbio.asm.org 3
 
m
bio.asm
.org
 o
n
 M
arch 6, 2018 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
the nature of the B-cell response was examined in more depth. Mice immunized i.p.
with 1 g of STmGMMA showed a clear induction of splenic germinal centers (GC) and
GC B cells at 4 days after immunization (Fig. 2A and B). Numbers of GC B cells increased
further after a second immunization with 1 g of STmGMMA (Fig. 2B). Indeed, immu-
nization induced a rapid increase in activated CD4 T cells in the spleen by day 7,
including a 3-fold increase in T follicular helper-like (Tfh) cells (Fig. 2C). Accompanying
these features was an increase in the numbers of plasma cells, including cells that
had switched to IgG2b and IgG2c (Fig. 2D). Taken together, these results show that
STmGMMA induce a rapid and extensive T- and B-cell response.
Ab responses to LPS and porins within STmGMMA develop with distinct
kinetics. The rapid IgG response to STmGMMA observed led us to question whether
this was induced similarly to multiple antigens within the particles or if responses
within the same antigenic complex developed with distinct kinetics. To evaluate this,
the responses to two immunodominant antigens, LPS and porins, were examined.
Assessment of the B-cell response by enzyme-linked immunosorbent spot (ELISPOT)
assay was used to assess antigen-speciﬁc IgM- and IgG-producing cells in the spleen at
different time points following immunization with 1 g of STmGMMA. IgM Ab-
secreting cells (ASC) secreting Abs speciﬁc to both antigens were detected in the spleen
at days 4 and 7 after immunization, albeit at higher frequencies for porins than for
LPS. In contrast, IgG ASC speciﬁc to LPS were largely absent at both days 4 and 7
postimmunization, whereas IgG ASC speciﬁc to porins were readily detectable, and at
an increasing frequency, at these two times (Fig. 3A). This nonparallel response was also
reﬂected in the titers of Abs to both antigens in serum (Fig. 3B). IgG binding to LPS was
not inhibited because of the presence of anti-LPS IgM antibodies, since depletion of
IgM from serum samples with a speciﬁc monoclonal Ab (MAb) did not result in the
detection of higher anti-LPS IgG titers (see Fig. S1 in the supplemental material).
Enzyme-linked immunosorbent assays (ELISAs) were performed with serum samples
from mice immunized with STmGMMA for 7 days or boosted for 4 days and digested
with pepsin to generate F(ab=)2, Fab, and Fv fragments of IgM. These experiments
showed that these fragments could still bind to LPS and porins, but the signal detected
was weaker than that detected for IgM in undigested serum samples (Fig. S2). Thus,
serum IgG to porins is detectable for days before IgG against LPS is detected. Analysis
showed that at day 7, all subtypes except IgG1 against porins are present. Despite this
early variability, by day 35, Abs of all subtypes to both LPS and porins were readily
found (Fig. 3B). Therefore, although the host can clearly respond to multiple compo-
nent antigens within a single antigenic complex, responses to the individual antigens
present within GMMA can develop with distinct kinetics.
STmGMMA induce T-cell-independent switching to all IgG isotypes except
IgG1. Although a humoral response associated with T-cell activation is seen after
STmGMMA immunization, the surprisingly rapid and complex Ab response suggested
that the response may include a T-cell-independent component. We therefore immu-
nized T-cell-deﬁcient mice with STmGMMA and determined the titers of IgM and IgG to
STmGMMA in serum 7 days later. Both IgM and IgG were induced by 7 days after
immunization in the absence of T cells (Fig. 4A). The T-cell-independent response to
puriﬁed S. Typhimurium porins involves B1b cells (33). To establish if immunization with
STmGMMA induced a B1b cell response, wild-type (WT) and T-cell-deﬁcient mice were
immunized with STmGMMA and the proportion of peritoneal B1 cells that are B1b cells
was determined at 4 and 7 days after immunization. The proportion of B1b cells
increased after STmGMMA immunization in both WT and T-cell-deﬁcient mice, indicat-
ing that STmGMMA induce B1b responses (Fig. 4B). Assessment of responses by
ELISPOT assay and ELISA 7 days after immunization showed that IgM to LPS and porins
was induced in T-cell-deﬁcient mice (Fig. 4C and D). Surprisingly, assessment of the
speciﬁc responses to LPS and porins by ELISPOT assay and serology showed that in
T-cell-deﬁcient mice, there was a selective induction of antigen-speciﬁc IgG to porins,
but not LPS, and that all IgG isotypes were induced at days 7 and 14, with the exception
of IgG1 (representative results for day 7 are shown in Fig. 4C to E). Similar results were
Schager et al. ®
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FIG 2 STmGMMA induce rapid and extensive B- and T-cell responses after immunization. Mice were immunized
i.p. with 1 g of STmGMMA for the times indicated in days following primary immunization. (A) Representative
photomicrographs of spleen sections from nonimmunized mice and mice immunized with STmGMMA stained
for IgD (brown) and CD3 (blue; top row) or PNA (blue; bottom row) for nonimmunized WT mice (left) and mice
immunized for 4 (middle) or 7 (right) days. Scale bar, 100 m. (B to D) Representative FACS plots demonstrating
gating and enumeration of cells (all from mice immunized for 7 days) from spleens stained for GC B (GCB) cells
(CD3 F4/80-B220 is Fas and GL7 positive) (day 39 indicates mice boosted at day 35) (B), splenic activated T cells
(CD3 CD44 CD4) (left graph) and Tfh cells (CD3 CD44 CD4 is CXCR5 PD1) (right graph) from a mouse
immunized for 7 days (C), and plasma cells (CD3 B220lo CD138) (left graph), including plasma cells stained
positive for intracellular IgG2b (middle graph) or IgG2c (right graph) (D). Graphs show the mean value and
standard deviation of four mice per group, and the results are representative of two independent experiments.
T, T zone; Re-imm, reimmunization. Statistical analysis was performed with the Kruskal-Wallis test and Dunn’s
multiple-comparison test, with time zero as the reference time point. The Mann-Whitney U test was used to
compare the day 35 and 39 time points in panel B. NS, nonsigniﬁcant; *, P  0.05; **, P  0.01; ***, P  0.001.
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also observed at day 14, including a failure to detect antigen-speciﬁc IgG1. Therefore,
immunization of mice lacking T cells shows that STmGMMA induce a strong T-cell-
independent response and reveals a key role for T cells in the promotion of switching
to IgG1.
STmGMMA induce long-term responses to both LPS and porins. A highly
desirable feature of a vaccine is to induce responses that will persist. Therefore, we
examined the response to porins and LPS in the spleen and bone marrow (BM) at later
times after immunization. Furthermore, since O-Ag has been hypothesized to limit Ab
binding to the Gram-negative bacterial surface, we assessed if removing O-Ag from
GMMA could augment the Ab response to porins after immunization. Mice were
immunized at time zero and boosted 14 days later with 1 g of STmGMMA that were
O-Ag replete (O-Ag) or deﬁcient (O-Ag), and the response was examined 14 or
203 days later. Robust antigen-speciﬁc B-cell responses to LPS and porins were ob-
served after immunization with O-Ag STmGMMA in both the spleen and the BM at
days 14 and 203 (Fig. 5A). After immunization with O-Ag STmGMMA, there was not a
dramatic change in the anti-porin B-cell response, and thus, the loss of O-Ag from
FIG 3 Nonparallel Ab responses to LPS and porins develop after immunization with STmGMMA. WT mice were immunized
i.p. with 1 g of GMMA for the times indicated. (A) B-cell ELISPOT assay used to assess IgM (left) and IgG (right) ASC
against LPS (closed circles) and porins (open circles) in spleens 4 and 7 days after immunization. Numbers of spot-forming
units (SFU) per million splenocytes are depicted in the graphs alongside representative pictures of wells after development.
Each circle represents one mouse, and pooled results of three experiments are shown, except for the day 4 results, which
are from two experiments with at least three mice per group. (B) Relative Ab titers, as determined by ELISA, in serum
samples against LPS (closed circles, solid line) or porins (open circles, dashed line) from mice immunized with STmGMMA
for the times indicated. Each circle represents the mean value of four mice  the standard deviation. The dotted vertical
line represents the time point of reimmunization (Re-imm). The Mann-Whitney U test with Bonferroni correction for
multiple comparisons was used to determine signiﬁcant differences between groups linked by bars. NS, nonsigniﬁcant; *,
P  0.05; **, P  0.01; ***, P  0.001.
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GMMA is not sufﬁcient to promote a lasting increase in the porin-speciﬁc response
(Fig. 5A and B). There was a surprising response to LPS in mice that received O-Ag
STmGMMA (Fig. 5A). Such antibodies are likely to target non-O-Ag and noncore regions
of the LPS molecule since serology conﬁrmed that there was a minimal response to the
FIG 4 STmGMMA induce an early T-cell-independent anti-porin IgG response that is associated with B1b cells. (A)
T-cell-deﬁcient (TCR/) mice were immunized i.p. with 1 g of STmGMMA for 7 days, and serum samples were
analyzed by ELISA for anti-STmGMMA IgM (left) and IgG (right). Each dot represents one serum sample. (B) WT or
TCR/ mice were immunized with 1 g of STmGMMA for the times stated, and representative FACS gating for B1b
cells from peritoneal cavity ﬂushes is shown. B1 cells were identiﬁed as IgM CD19 CD21lo CD23lo, and B1b cells were
identiﬁed as B1 cells that were CD5 B220 (representative FACS plots to demonstrate gating are from TCR/ mice
immunized for 7 days). Frequencies of B1b cells in B1 cells of WT (left) and TCR/ (right) mice at the postimmunization
time points indicated are shown in the graphs. Each dot represents one mouse, and pooled results of two experiments
are shown. (C) IgM (left) and IgG (right) ASC against LPS (closed circles) or porins (open circles) in the spleens of
TCR/ mice immunized with STmGMMA for 7 days identiﬁed by B-cell ELISPOT assay. Numbers of spot-forming units
(SFU) per million splenocytes are depicted in the graphs alongside representative pictures of wells after development. Each
dot represents one mouse, and pooled results of multiple experiments are shown. (D) TCR/ mice were immunized
with STmGMMA for 7 days, and titers of IgM (left) and IgG (right) against LPS (closed circles) or porins (open circles) in
serum samples were analyzed by ELISA. Each dot represents one serum sample, and the results are representative of two
independent experiments. (E) TCR/mice were immunized with STmGMMA for 7 days, and IgG isotypes against porins
in serum samples were analyzed by ELISA. Graphs show the mean values and standard deviations of groups of four mice.
NI, nonimmunized. Statistical analysis was performed with the Kruskal-Wallis test and Dunn’s multiple-comparison test,
with time zero as the reference time point for the left graph in panel B, and the Mann-Whitney U test was used for the
right graph in panel B and for panel C. NS, nonsigniﬁcant; **, P  0.01; ***, P  0.001.
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O-Ag and core oligosaccharide puriﬁed from S. Typhimurium in this group (Fig. 5B).
Therefore, STmGMMA induce persisting Ab responses in the BM and spleen after
immunization.
The presence of O-Ag in STmGMMA enhances protection in the spleen. It is
clear from previous studies that Ab to O-Ag, generated after natural infection or after
immunization with an O-Ag conjugate vaccine, can protect against infection (26, 30, 36,
FIG 5 The persistence of Ab responses against LPS and porins following STmGMMA immunization. CD1 WT mice were
immunized i.p. with 1 g of STmGMMA O-Ag (open squares) or O-Ag (open triangles) at time zero and day 14. (A) B-cell
ELISPOT assay used to assess IgG ASC against LPS and porins in spleen (left) and BM (right) 14 (top) or 203 (bottom) days
after the second immunization. Splenocytes from each mouse were used to seed wells in triplicate at 5  105/well.
Numbers of spot-forming units (SFU) per million splenocytes are depicted in the graphs, and to the right are representative
wells after development. Each dot represents one mouse. (B) ELISA used to analyze titers of IgG against O-Ag (left) or porins
(right) in serum samples from mice immunized twice with either STmGMMA O-Ag (red circles) or O-Ag (blue circles) for
the time periods indicated. Each circle represents one serum sample. The Mann-Whitney U test with Bonferroni correction
for multiple comparisons was used to determine signiﬁcant differences between groups linked by bars. NI, nonimmunized;
NS, not signiﬁcant;*, P  0.05; **, P  0.01.
Schager et al. ®
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37). Nevertheless, STmGMMA are known to contain other antigens, such as OmpD (33),
that are targets of protective antibodies. Therefore, we tested the level of protection
observed after immunization with O-Ag or O-Ag STmGMMA. Mice were immunized
twice, 14 days apart, with the different STmGMMA and then challenged with S. Typhi-
murium, and the bacterial burdens were assessed 3 days later (Fig. 6). Mice immunized
with both types of STmGMMA had bacterial burdens in the liver and spleen that were
signiﬁcantly lower than those of nonimmunized mice (Fig. 6). Nevertheless, mice
immunized with O-Ag STmGMMA had markedly lower bacterial numbers in the
spleen than mice immunized with O-Ag STmGMMA (typically, a 70-fold difference
in mean bacterial numbers). Mice immunized with O-Ag STmGMMA also had lower
bacterial burdens in the liver than mice that received O-Ag STmGMMA, but this
difference was more marginal (typically, an ~10-fold difference in mean bacterial
numbers). Thus, immunization with STmGMMA deﬁcient in O-Ag can reduce infection
in the spleen and liver, but the presence of O-Ag can enhance this protection and this
effect is more pronounced in the spleen than in the liver.
DISCUSSION
Previous work has shown that immunization with OMVs can protect against infec-
tion (1, 8, 10–17). Vaccines based on OMVs may offer an advantage over other
strategies, such as O-Ag conjugates, through increased coverage of antigens in their
natural conformation, their simplicity and cost of production, and their intrinsic adju-
vant activity. In this study, we have shown that there is a strong dependence on B cells
for the protection afforded by immunization with STmGMMA. Furthermore, while Ab
induced by STmGMMA that lacks O-Ag is protective, the presence of O-Ag in the
particles can bolster this protection, particularly in the spleen. Our evidence also
suggests that the Ab response to STmGMMA is long-lived, as 200 days after immu-
nization, there was a signiﬁcant and persisting number of ASC speciﬁc for LPS and
porins in the BM. B cells can provide Ab-dependent and -independent protection
against infection. Nevertheless, in this instance, Ab is likely to make a major contribu-
tion, since opsonization of bacteria with serum samples from immunized mice is
sufﬁcient to reduce colonization and the absence of O-Ag reduces the protection
afforded by immunization (37).
Loss of the immunodominant O-Ag (28, 30) from STmGMMA reduced the protection
afforded by immunization, although bacterial burdens in the spleen and liver were still
20-fold lighter than those of nonimmunized controls. However, compared to O-Ag
STmGMMA, the presence of O-Ag in STmGMMA was associated with a greater en-
hancement of protection in the spleen than in the liver. This suggests that the
contribution of protective Ab to O-Ag varies for STmGMMA at different sites. Since Abs
to S. Typhimurium largely protect through cell-dependent mechanisms in mice (38), it
is likely that these differences reﬂect the types of immune cells present in various
organs at different stages of infection (39). Other reasons for these differences include
FIG 6 Immunization with O-Ag STmGMMA offers protection against infection in the spleen and liver.
CD1 mice were immunized with STmGMMA O-Ag or O-Ag at time zero and day 14 and subsequently
challenged i.p. with 2  104 CFU of S. Typhimurium SL1344 at day 28. Bacteria in the spleen (left) and
liver (right) were enumerated 3 days after infection. Each circle represents one mouse, and graphs are
representative of two independent experiments. One-way ANOVA with Tukey’s multiple-comparison test
were used to determine signiﬁcant differences between groups linked by bars. NI, nonimmunized;*, P 
0.05; **, P  0.01; ***, P  0.001.
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potentially the levels of O-Ag expression by bacteria entering these sites, the nature of
the model, or other unappreciated reasons. Nevertheless, what is not clear is whether
such differences are clinically meaningful, as it is not known what reduction in bacterial
numbers is necessary to protect against disease. In reality, the level of protection
needed to prevent disease is likely to depend upon the magnitude of the dose required
to cause an infection within an individual, which will vary depending upon factors such as
nutritional status, immune status, and geographic location. Since quantitative culture
studies show that the bacteremia detected in patients with iNTS disease and HIV coinfec-
tion is low, in the order of a few bacteria per milliliter (40), it may mean that only modest
levels of protection by a vaccine are needed. Indeed, the period between loss of maternal
Ab and the ﬁrst acquisition of IgG to NTS in infants is associated with an increased risk of
invasive disease (24). Therefore, nonsterilizing immunity could be sufﬁcient to provide
widespread protection in vulnerable groups. The data in the present study indicate that Ab
to surface antigens other than O-Ag can reduce bacterial numbers, and it is now necessary
to better understand the nature of these protective antigens and if they can be manipu-
lated to provide enhanced protection within a vaccine.
A single Gram-negative bacterium can contain millions of LPS molecules (41), and
each O-Ag can contain over a hundred repeats (42), although in GMMA, estimates
suggest that numbers of O-Ag repeats are lower than in WT bacteria (43). In contrast,
estimates of the numbers of porin molecules expressed per cell suggest there is
approximately 1 porin molecule for every 10 LPS molecules (44). Thus, epitopes
for the O-Ag are likely to be present in a signiﬁcant excess over those for porins. The
combination of a higher epitope frequency and the spatial localization of O-Ag, being
more distal from the cell surface than porins, makes the more rapid detection of
switching to IgG against porins surprising. The level of response to an antigen can be
important. In some individuals with HIV, atypically high titers of Ab to LPS O-Ag from
Salmonella have been shown to inhibit bacterial killing in a serum bactericidal assay
(31). Furthermore, a similar phenomenon has been observed in some patients with
bronchiectasis and concurrent Pseudomonas aeruginosa infection, and in this case, the
presence of inhibitory Ab correlates with worse disease (45). Therefore, examination of
the Ab responses to STmGMMA with and without O-Ag offered an opportunity to
examine whether O-Ag limited the development of Ab responses to other antigens. We
expected there to be an increase in the response to porins in the absence of O-Ag since
the access of B-cell receptors to these molecules on the bacterial surface could
reasonably be expected to be enhanced. With the exception of a small augmentation
of anti-porin Ab titers at day 14, we did not ﬁnd this to be the case. This may be because
responses to porins had already reached a peak level or because the tolR mutation can
result in O-Ag being shorter in GMMA, meaning that anti-porin responses are readily
induced anyhow (43), or because loss of wbaP inﬂuenced the frequency of LPS or porins
in the STmGMMA (46). Moreover, the modest size of spherical STmGMMA particles may
mean that O-Ag is not effective at occluding access to the surface of the GMMA.
Nevertheless, it suggests that the absence of O-Ag from STmGMMA does not increase
the frequency of the porin-speciﬁc Ab response.
IgM to LPS and porins was induced rapidly. When digested serum samples contain-
ing F(ab=)2, Fab, and Fv fragments of IgM were used in ELISAs, a reduced IgM signal,
compared to that in undigested serum samples, was detected in anti-LPS ELISAs. This
difference was greater in serum samples from mice immunized for 7 days than in
samples from mice boosted with STmGMMA. Therefore, while IgM does not necessarily
need to be in pentameric form to bind to these antigens, it is probable that the higher
avidity of undigested IgM aids binding to LPS, particularly at earlier time points after
immunization. Nevertheless, other factors may contribute to the degree of difference
observed between digested and undigested serum samples. For instance, there may be
fewer epitopes available on digested than nondigested IgM for the secondary Ab used
in the ELISA to bind to, and this may alter the intensity of the signal detected. Further
experiments are needed to understand fully the role of IgM avidity in Ab binding to
these antigens. In contrast to IgM, the IgG response to porins and LPS developed with
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distinct kinetics after immunization with STmGMMA, despite both antigens being
located in the same antigenic complex. IgG to porins was detectable at 4 days after
infection, whereas IgG to LPS was not detectable until after a week. While some of this
may reﬂect differences in germline afﬁnities of antibodies (47), it was still surprising
considering the rapid detection of IgM to both antigens and that LPS O-Ag is stoichi-
ometrically the predominant antigen, with each individual O-Ag typically containing
multiple repeats of the same epitope. Both LPS and porins have been reported to
induce T-cell-independent responses when given as puriﬁed antigens (33, 48). Porin
proteins, like OmpD, probably induce T-cell-independent responses through a combi-
nation of their capacity to oligomerize into units of trimers and their ability to interact
with Toll-like receptor 2 (TLR2) and TLR4, and the latter property is lost if the proteins
are digested with proteinase K (49). STmGMMA induced B1b-cell responses in WT and
T-cell-deﬁcient mice, and our previous work found that live S. Typhimurium and porins
could induce responses in this B-cell subset (33). Antigens derived from pathogens that
induce B1b responses are typically targets of protective immunity, and multiple anti-
gens that induce B1b-cell responses, such as pneumococcal polysaccharide and the Vi
capsular polysaccharide from S. Typhi, are used as vaccines in humans (35, 50). This
reinforces the concept that identiﬁcation of B1b antigens may be a helpful strategy to
identify candidate antigens for vaccines.
The strong T-cell-independent response to porins within STmGMMA was associated
with the early induction of IgG2b, IgG2c, and IgG3. Indeed, the only feature of the
response dependent upon T cells was the induction of speciﬁc IgG1, an isotype we have
reproducibly found to be poorly detected after infection with live S. Typhimurium (32).
Moreover, in the response to live organisms, we and others have observed that T cells
and molecules associated with classical T-dependent responses such as CD28, CD40-
ligand, and ICOS (32, 33, 51, 52) are required for a signiﬁcant IgG2a or IgG2b response.
An additional difference between the responses to STmGMMA and live S. Typhimurium
is the extensive early GC response, which is absent after live S. Typhimurium adminis-
tration and something that live S. Typhimurium can actively suppress (47, 53, 54).
Therefore, the cell surface antigens present in STmGMMA cannot be sufﬁcient on their
own to be responsible for these differences and the suppression of early GC formation
observed after live infection. It is possible that the T-cell-independent switching to
IgG2a seen after immunization with STmGMMA reﬂects more what is seen after
infection with viruses and virus-like particles (55).
The speed of induction of the GC seen after STmGMMA was striking and resembles
that observed after immunization of mice with the T-cell-independent antigen NP-
Ficoll, where there is a high frequency of antigen-speciﬁc B cells (56). A recent study
showed that T-cell-independent switching to IgG against a peptide antigen within
liposomes was strictly dependent on concomitant signaling via TLR4 and TRIF (57).
Therefore, the multiple TLR4 ligands found in STmGMMA could modulate the response
to other antigens within the complex. This means that ultimately the Ab response to
the same antigen can vary dramatically, depending upon the context in which the
antigen is encountered, for instance, whether the antigen is part of a viable organism,
in a complex with other antigens, or entirely in isolation. Indeed, we have previously
shown that the pattern of IgG switching to ﬂagellin from S. Typhimurium varies
dramatically, depending upon whether mice encounter ﬂagellin as a puriﬁed molecule
or in its native context, attached to the surface of a live organism (51). An appreciation
of how to control the direction of IgG switching to an antigen will help us understand
how to maximize the potential of OMVs and GMMA as platforms for vaccine delivery.
MATERIALS AND METHODS
STmGMMA production, puriﬁcation, characterization, and electron microscopy. Hyperblebbing
GMMA-producing strains (provided by the GSK Vaccines Institute for Global Health) and the production
and puriﬁcation of GMMA were performed as described previously (3, 6, 58). In brief, the tolR gene in
S. Typhimurium isolate 1418 (59) was replaced with the kanamycin resistance gene aph (3, 6, 43). For the
generation of a GMMA-producing strain lacking the O-Ag, wbaP was replaced with the chloramphenicol
resistance cassette (cat). Forward and reverse primers with approximately 50 bp homologous to
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upstream and downstream regions of the gene to be deleted and approximately 20 bp corresponding
to ﬂanking regions of the respective resistance cassette were used to amplify replacement constructs.
The primers used for aph resistance replacement are reported elsewhere (6), and the primers used for cat
resistance replacement were 5= CGCAGGCTAATTTATACAATTATTATTCAGTACTTCTCGGTAAGCGTGTAGGC
TGGAGCTGCTTCG 3= and 5= CTTAATATGCCTATTTTATTTACATTATGCACGGTCAGAGGGTGACATATGAATA
TCCTCCTTAG 3=. Amplicons were then puriﬁed and transformed into S. Typhimurium 1418 with the
lambda phage recombinant system (red operon) located on pAJD434 as described in reference 3. A
speciﬁc anti-O:4 LPS O-Ag MAb (provided by the GSK Vaccines Institute for Global Health) was used to
conﬁrm the loss of O-Ag from STmGMMA generated from this strain (25). To purify GMMA, 300 ml of
fresh LB medium was inoculated with bacteria from an overnight culture to generate a culture with an
optical density at 600 nm (OD600) of 0.05. Once the culture reached an OD600 of 0.7 to 1, it was incubated
for a further 3 h and then centrifuged for 10 min at 3,220  g. The supernatant containing GMMA was
ﬁltered through a 0.22-m ﬁlter and ultracentrifuged for 2 h at 186,000  g with a 45 or 70 Ti rotor
(Beckman Coulter, Inc.). GMMA were then resuspended in phosphate-buffered saline (PBS), ﬁltered
through a 0.22-m ﬁlter, and stored at 4°C until use. The total protein concentration of GMMA samples
was assessed by Lowry assay (Bio-Rad). For TEM, STmGMMA were ﬁxed in 2.5% glutaraldehyde–0.1 M
phosphate buffer and embedded in Epon-araldite resin, and 70- to 80-nm sections were cut and stained
with uranyl acetate and Reynolds lead citrate before being visualized with a JEOL 1200EX at the Centre
for Electron Microscopy at the University of Birmingham.
Mice, immunizations, and bacterial challenge strains. All of our animal studies had ethical
approval from the University of Birmingham and UK Home Ofﬁce approval and were performed under
project license 30/2850 in compliance with the Animals (Scientiﬁc Procedures) Act 1986. Inbred WT
C57BL/6 males 6 to 8 weeks old or outbred WT CD1 females 6 to 8 weeks old were obtained from OLAC
Harlan. In experiments, C57BL/6 mice were used as WT mice unless otherwise stated. TCR/ and
IgH/ (33, 60) mice on a C57BL/6 background were bred at the Biomedical Service Unit, University of
Birmingham. Mice were immunized via i.p. injection with STmGMMA O-Ag or O-Ag (the same 1-g
dose of protein was given in all of the experiments in this study) diluted in 200 l of PBS. Analysis showed
that the ratio of O-Ag to protein in STmGMMA O-Ag preparations was in the range of 0.7 to 0.9 part
O-Ag to 1 part total protein (wt/wt). For protection studies, S. Typhimurium attenuated AroA strain
SL3261 (described in reference 32) and virulent strain SL1344 were used at infection doses of 5 105 and
2  104 CFU, respectively, and administered i.p. in PBS. Opsonization experiments were performed as
described in reference 32, with multiple nonpooled serum samples from nonimmunized mice or mice
that had been immunized with STmGMMA for 35 days. Prior to use, serum samples were heated for
30 min at 56°C to inactivate complement. Infection doses of S. Typhimurium SL3261 and serum samples
(1:100) were then mixed for 30 min at room temperature before infection. Bacterial viability and lack of
agglutination in the presence of opsonizing Ab were conﬁrmed by plating bacteria onto agar and
ensuring that they grew as discrete colonies at the appropriate frequency. Bacterial numbers were
determined by direct culturing of homogenized spleen and liver samples.
ELISA and ELISPOT assay. Antigens used in ELISAs and ELISPOT assays were STmGMMA O-Ag,
porins (OmpC, OmpF, and OmpD) puriﬁed from S. Typhimurium (described in references 33 and 61), TLR
grade S. Typhimurium LPS (Axxora ALX-581-011-L002), or O-Ag (with core sugars attached) puriﬁed from
S. Typhimurium 1418 (provided by the GSK Vaccines Institute for Global Health and described in
reference 62). All antigens were used at 5 g/ml, and ELISAs were performed as previously described (32).
Mouse serum was added to wells and then serially diluted, and the presence of bound Ab was detected
with isotype-speciﬁc alkaline phosphatase (AP)-conjugated goat anti-mouse Abs (Southern Biotech) and
developed with Sigma FAST p-nitrophenylphosphate tablets. Titers were calculated by identifying the
dilution at which the signal reached a set OD405.
To obtain splenic cells for ELISPOT assay and ﬂow cytometry, spleens were disrupted through a
70-m cell strainer into Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) supplemented with
10% heat-inactivated fetal bovine serum and 5% penicillin-streptomycin (complete RPMI). BM cells were
obtained by ﬂushing one hind leg (femur and tibia) per mouse with RPMI 1640 medium. Erythrocytes
were lysed with ammonium-chloride-potassium lysis buffer (Gibco). Single-cell suspensions were washed
in complete RPMI 1640 medium and resuspended to the desired concentrations. For ELISPOT assay,
multiscreen ﬁlter plates (Merck Millipore) were coated with antigen diluted in PBS overnight at 4°C,
washed with PBS, and then blocked with complete RPMI 1640 medium for 1 h at 37°C. The wells were
then washed once with PBS, and 5  105 cells from spleen or BM were seeded per well in 200 l of
complete RPMI 1640 medium, each sample in triplicate. Plates were then incubated for 6 h at 37°C in 5%
CO2. After incubation, cells were lysed and washed away with PBS–0.05% Tween. Bound mouse Ab was
detected with goat anti-mouse Ab linked to AP (Southern Biotech) diluted in PBS overnight at 4°C. The
following day, wells were washed three times with PBS–0.05% Tween and once with PBS. Spots were
developed with Sigma FAST 5-bromo-4-chloro-3-indolylphosphate (BCIP)–Nitro Blue Tetrazolium tablets
(Sigma) diluted in sterile water in accordance with the manufacturer’s instructions.
Depletion of IgM from serum samples and digestion of serum samples to generate IgM F(ab=)2,
Fab, and Fv. Monoclonal rat anti-mouse IgM (clone 1B4B1; Southern Biotech) was conjugated to
Sepharose 4B (GE Healthcare) in accordance with the manufacturer’s protocol. Two hundred microliters
of bead slurry was mixed with 200 l of serum for 15 min. Beads were centrifuged at low speed. The
supernatant, containing depleted serum, was compared with undepleted serum by ELISA to assess IgG
and IgM contents and antibodies speciﬁc for LPS and porins. Relative levels of IgM and IgG in the serum
samples were assessed by ELISA by the basic technique described above but with the following differences.
The capture Ab in the ELISAs was the rat anti-mouse IgM used as described above or unlabeled sheep
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anti-mouse IgG (both used to coat plates at 1 g/ml), and secondary antibodies were HRP-conjugated goat
anti-mouse kappa light chain (Millipore) for IgM and goat anti-mouse heavy and light chains (Southern
Biotech) for IgG. Color was developed with 3,3=5,5=-tetramethylbenzidine dihydrochloride tablets (Sigma) and
H2SO4 in accordance with the manufacturer’s instructions. The OD450 was measured.
IgM F(ab=)2, Fab, and Fv fragments from serum samples were generated by adapting a previously
described method (63). Serum samples were diluted with an equal amount of 20 mM sodium acetate,
pH 4.5, and adjusted to a pH of 4.0 with HCl. Immobilized pepsin (Thermo Scientiﬁc) was then added to
these serum samples at a ratio of resuspended enzyme beads to serum of 1:50, and the mixture was
incubated at 37°C with shaking for 24 h. The reaction was stopped by removal of the pepsin beads after
centrifugation at 1,000  g for 5 min. Digestion of IgM into F(ab=)2, Fab, and Fv fragments was veriﬁed
by SDS-PAGE. Serum samples were then diluted in PBS, and the pH was conﬁrmed to be in the range of
7 to 7.5 before they were used in ELISAs.
Fluorescence-activated cell sorter (FACS) analysis. Cells from spleen or peritoneal ﬂushes were
stained with one or more of the following anti-mouse MAbs: CD3-ﬂuorescein isothiocyanate (FITC),
CD3-phycoerythrin (PE)/Cy7 (145-2C11), GL7-eFluor 450 (GL7), F4/80-FITC (BM8), CD4-eFluor 450 (RM4-5),
CD44-peridinin chlorophyll protein (PerCP)-Cy5.5 (IM7), PD-1–PE (J43), IgM-PE-Cy7 (11/41), and CD5-
PerCP-Cy5.5 (53-7.3) from EBioscience; B22 0PE (RA3-6B2), CD95-PE-Cy7 (Jo2), CD19-allophycocyanin
(APC)-Cy7 or -APC (ID3), CD21-FITC (7G6), and CD23-PE (B3B4) from BD Pharmingen; B220BV510
(RA3-6B2) and CD138-PE (281-2) from BioLegend; and IgG2b-FITC and IgG2c-FITC (polyclonal) from
Southern Biotech. Rat anti-mouse CXCR5 (551961) (BD Pharmingen) was detected with an Alexa Fluor
647-conjugated anti-rat antibody (712-606-153) from Jackson ImmunoResearch, Inc. Cells were then
assessed on a CyAn ADP ﬂow cytometer and analyzed with FlowJo 9.3.2. (TreeStar). For intracellular
staining, cells were ﬁrst stained for surface markers and then ﬁxed and permeabilized with Cytoﬁx/
Cytoperm Plus (BD Biosciences).
Immunohistology. Spleens were processed and stained as described previously (32). In short,
spleens were frozen in liquid nitrogen and 5.5-m-thick sections were cut and allowed to dry before
ﬁxation in acetone for 20 min at 4°C. In all cases, antibodies were added for 45 min of incubation at room
temperature. Sheep anti-mouse IgD (Abcam) was detected with peroxidase-labeled donkey anti-sheep
antibody (Jackson ImmunoResearch, Inc.) and developed with 3,3=-diaminobenzidine tablets (Sigma).
CD3 and peanut agglutinin (PNA) were detected with rat anti-mouse CD3 (AbD Serotec), biotinylated
rabbit anti-rat (Dako), and biotinylated rabbit anti-PNA (Vector Laboratories) antibodies. Biotinylated Ab
binding signal was developed by using a streptavidin-biotinylated AP complex (Vectastain; Vector
Laboratories) with Naphthol AS-MX phosphate, levamisole, and Fast Blue Salt.
Statistical analyses. Statistical tests were performed with Prism software. The tests performed are
indicated in the legends but included the Kruskal-Wallis test with Dunn’s multiple-comparison test, the
two-tailed Mann-Whitney U test (with Bonferroni correction for multiple comparisons if required), and
one-way analysis of variance (ANOVA), followed by Tukey’s multiple-comparison test. P  0.05 was
considered signiﬁcant.
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FIG S1, TIF ﬁle, 0.1 MB.
FIG S2, TIF ﬁle, 0.3 MB.
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